The drug industry notched its first initial win at the appellate level when the Fifth Circuit on Friday (Sept. 20) partially reversed a Texas district court’s decision to dismiss the brand drug lobby’s lawsuit against further implementation of the Inflation Reduction Act’s Medicare drug negotiation program. Several district courts around the country have dismissed industry suits against the negotiation program, leaving stakeholders looking to appeals courts’ decisions for next steps on the litigation that could eventually wind its way to...